Prevalence and Factors Associated With Atrial Fibrillation in Patients With Type 2 Diabetes

Prevalence and Factors Associated With Atrial Fibrillation in Patients With Type 2 Diabetes: A Case-Control Study

This case-control study was conducted at Burapha University Hospital. The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.

Study Overview

• Status: Completed
• Conditions: Atrial Fibrillation; Type 2 Diabetes
• Intervention / Treatment: Other: Routine examinations

• Study Type: Observational
• Enrollment (Actual): 427

Contacts and Locations

Study Locations

• Thailand
  • Chonburi
    • Mueang, Chonburi, Thailand, 20131
      • Burapha University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Outpatients with type 2 diabetes who visited the medical clinic at Burapha University Hospital, Chonburi province, Thailand between June 2022 and June 2023 were enrolled in the present study.

Description

Inclusion Criteria:

• Outpatients with type 2 diabetes who visited the medical clinic between June 2022 and June 2023

Exclusion Criteria:

• Patients with missing information on the urinary albumin value and electrocardiograms at the latest date

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Type 2 diabetes patients with atrial fibrillation; The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.	Other: Routine examinations; Electrocardiography and clinical parameters examinations, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications
Type 2 diabetes patients without atrial fibrillation; The 12-lead electrocardiography recordings of type 2 diabetes patients were reviewed by a cardiologist to confirm the presence of atrial fibrillation. The clinical parameters, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications were analyzed and compared between atrial fibrillation and non-atrial fibrillation patients.	Other: Routine examinations; Electrocardiography and clinical parameters examinations, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of atrial fibrillation	Prevalence of atrial fibrillation in patients with type 2 diabetes	June 2022 and June 2023
Factors associated with atrial fibrillation	Factors associated with atrial fibrillation in patients with type 2 diabetes, including age, hypertension, heart failure, thyroid disease, type 2 diabetes duration, body mass index, estimated glomerular filtration rate, glycated hemoglobin, presence of albuminuria, and use of diuretic medications	June 2022 and June 2023

Collaborators and Investigators

• Sponsor: Burapha University

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2022
• Primary Completion (Actual): June 30, 2023
• Study Completion (Actual): July 31, 2023

Study Registration Dates

• First Submitted: December 8, 2023
• First Submitted That Met QC Criteria: December 8, 2023
• First Posted (Actual): December 18, 2023

Study Record Updates

• Last Update Posted (Actual): December 18, 2023
• Last Update Submitted That Met QC Criteria: December 8, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Arrhythmias, Cardiac; Diabetes Mellitus; Diabetes Mellitus, Type 2; Atrial Fibrillation
• Other Study ID Numbers: HS114/2565

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is no plan to make individual participant data available to other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No